Page last updated: 2024-12-11

g(m1) ganglioside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9963963
CHEBI ID61048
MeSH IDM0008923

Synonyms (28)

Synonym
g(m1) ganglioside
alpha-neu5ac-(2->3)-[beta-d-gal-(1->3)-beta-d-galnac-(1->4)]-beta-d-gal-(1->4)-beta-d-glc-(1<->1')-n-stearoylsphingosine
(neu5ac)gm1
alpha-neu5ac-(2->3)-[beta-d-gal-(1->3)-beta-d-galnac-(1->4)]-beta-d-gal-(1->4)-beta-d-glc-(1<->1')-n-octadecanoylsphingosine
galbeta1->3galnacbeta1->4(neuacalpha2->3)galbeta1->4glc-cer
CHEBI:61048 ,
(2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-[beta-d-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-d-galactopyranosyl-(1->4)]-beta-d-galactopyranosyl-(1->4)-be
galbeta1->3galnacbeta1->4(neu5acalpha2->3)galbeta1->4glcbeta1->1-cer
alpha-neup5ac-(2->3)-[beta-d-galp-(1->3)-beta-d-galpnac-(1->4)]-beta-d-galp-(1->4)-beta-d-glcp-(1<->1')-n-stearoylsphingosine
ganglioside g4
ganglioside m1
sialosylganglio-n-tetraosylceramide
ganglioside gm1
EPITOPE ID:142077
QPJBWNIQKHGLAU-IQZHVAEDSA-N
ganglioside gml
562413257Z ,
116950-37-9
gm1 d18:1/18:0
ganglioside gm1 (d18:1/18:0)
monosialotetrahexosylganglioside (d18:1/18:0)
unii-562413257z
siagoside hydrate
ganglioside gm1 [mi]
ganglioside g1
Q27130590
ganglioside gm1 (stereochemistry specified)
ganglioside gm1, ammonium salt, bovine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Solutions of TOPA were also toxic to mesencephalic neurons after acute or chronic exposure, displaying the same leftward shift in LD50."( Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G, 1992
)
0.28
"Studies were performed to characterize the toxic effects of human rIL-2 in mice and to examine the mechanism of toxicity."( Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Anderson, TD; Gately, MK; Hayes, TJ, 1988
)
0.27
" Although 99% less toxic than CT, procholeragenoid was only slightly less efficient in causing jejunal anti-CT responses in rats; in contrast, choleragenoid, the nontoxic B subunit pentamer of CT, was much less effective."( Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera.
Craig, JP; Cray, WC; Fürer, E; Germanier, R; Pierce, NF; Sacci, JB, 1983
)
0.27
" Under these conditions, GM1 ganglioside proved to be safe and well tolerated."( GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.
Chapas-Crilly, J; Rao, J; Roeltgen, DP; Rothblat, DS; Schneider, JS; Seraydarian, L, 1995
)
0.29
"Cultures of septal and hippocampal neurons from fetal rat and dorsal root ganglion neurons from embryonic chick were pretreated with GM1 ganglioside or cycloheximide and then supplemented with toxic concentrations of ethanol."( Ethanol neurotoxicity in vitro: effects of GM1 ganglioside and protein synthesis inhibition.
Heaton, MB; Paiva, M; Swanson, DJ; Walker, DW, 1994
)
0.29
" GM-1 use was not associated with differences in frequency, nature, or severity of adverse experiences."( Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial.
Bruno, R; Carolei, A; Dorsey, FC; Easton, JD; Gent, M; Grigoletto, F; Lenzi, GL; Roberts, RS; Rocca, WA; Walker, MD, 1994
)
0.29
"These findings suggest that GM-1 is safe in the dose and treatment schedule used and that its efficacy in ischemic stroke is greater when given soon after onset of stroke."( Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial.
Bruno, R; Carolei, A; Dorsey, FC; Easton, JD; Gent, M; Grigoletto, F; Lenzi, GL; Roberts, RS; Rocca, WA; Walker, MD, 1994
)
0.29
" In this study, we have investigated the potential protective effects of two well characterized growth factors, epidermal and basic fibroblast growth factor (EGF and bFGF respectively), and the monosialoganglioside GM1, on cultured rat retinal neurons submitted to toxic levels of excitatory amino acids."( Peptide growth factors but not ganglioside protect against excitotoxicity in rat retinal neurons in vitro.
Dreyfus, H; Heidinger, V; Hicks, D; Sahel, J, 1997
)
0.3
" We used three different experimental models to investigate their relevance to ischemic and excitotoxic conditions in the retina and have shown that: (a) both bFGF and EGF show highly effective neuroprotection for rat retinal neurons exposed to toxic levels of glutamate or its nonphysiological agonist kainate in vitro (b) retinal glial cells suffer morphological perturbations after glutamate or kainate treatment, and this effect depends on neuron-glial interactions; (c) these glial changes can also be corrected by posttreatment with either bFGF or EGF in vitro; (d) with the use of an in vivo animal model involving anterior chamber pressure-induced ischemia in adult rats, either pretreatment by intraperitoneal injection of GM1 or posttreatment by intraocular injection of the same ganglioside significantly reduces histological damage to inner nuclear regions."( Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia.
Dreyfus, H; Heidinger, V; Hicks, D; Mohand-Said, S; Sahel, J, 1998
)
0.3
" Our results showed that Abeta (1-40) was more toxic than Abeta (25-35) and the cytotoxicity of Abeta was proportional to its concentration."( Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide.
Chang, Y; Chen, LY; Chen, WY; Lin, MS; Wang, SS, 2008
)
0.35
"The loss of synapses and neurons in Alzheimer's disease (AD) is thought to be at least partly induced by toxic species formed by the amyloid beta (Aβ) peptide; therefore, therapeutics aimed at reducing Aβ toxicity could be of clinical use for treatment of AD."( Liposomes functionalized with acidic lipids rescue Aβ-induced toxicity in murine neuroblastoma cells.
Bereczki, E; Masserini, ME; Pei, JJ; Re, F; Winblad, B, 2011
)
0.37
" However, the presence of toxic aggregates in tissue raises the question of whether grafted stem cells are susceptible to amyloid toxicity before they differentiate into mature neurons."( Neuronal differentiation of human mesenchymal stromal cells increases their resistance to Aβ42 aggregate toxicity.
Benvenuti, S; Cascella, R; Cecchi, C; Cellai, I; Deledda, C; Evangelisti, E; Luciani, P; Peri, A; Saccardi, R; Stefani, M; Wright, D; Zampagni, M, 2011
)
0.37
") injections of the toxic 25-35 fragment of the Aβ peptide (Aβ alone group)."( Increased Expression of Simple Ganglioside Species GM2 and GM3 Detected by MALDI Imaging Mass Spectrometry in a Combined Rat Model of Aβ Toxicity and Stroke.
Caughlin, S; Cechetto, DF; Hepburn, JD; Jurcic, K; Park, DH; Whitehead, SN; Yeung, KK, 2015
)
0.42
" We showed that, contrarily to what expected from other amyloid studies, early aggregates of the mutant are not the most toxic species, despite their higher surface hydrophobicity."( Molecular insights into cell toxicity of a novel familial amyloidogenic variant of β2-microglobulin.
Bellotti, V; Bemporad, F; Bucciantini, M; Calamai, M; Canale, C; Giorgetti, S; Leri, M; Nosi, D; Oropesa-Nuñez, R; Pavone, FS; Ramazzotti, M; Stefani, M, 2016
)
0.43
" In the presence of the inhibitor of autophagy (3-methyladenine; 3-MA), the protective effect of GM1 on PC12 cells in Aβ (1-42) induced toxic conditions was diminished."( Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Aβ1-42-Induced Neurotoxicity and Cognitive Deficits.
Cai, W; Chen, H; Dai, R; Duan, W; Wang, Q; Wei, R; Yang, L; Zhang, S, 2017
)
0.46
" The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events."( Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020
)
0.56
" Its slow aggregation rate allows the purification of low molecular weight prefibrillar oligomers, which are the most toxic species."( Role of Electrostatic Interactions in Calcitonin Prefibrillar Oligomer-Induced Amyloid Neurotoxicity and Protective Effect of Neuraminidase.
Bonanni, R; Cariati, I; D'Arcangelo, G; Diociaiuti, M; Frank, C; Marini, M; Rinaldi, AM; Tancredi, V; Zarrilli, B, 2021
)
0.62
" This study was designed to clarify the relationship between plasma membrane composition in terms of the differently linked sialic acid (Sia) content and cell susceptibility to toxic and misfolded Aβ-42 peptides."( Correlation between Sialylation Status and Cell Susceptibility to Amyloid Toxicity.
Bucciantini, M; Delfino, G; Leri, M; Nosi, D; Sgambati, E; Tani, A; Zecchi-Orlandini, S, 2022
)
0.72
" However, recent experiments have shown that Aβ oligomers are more toxic to neurons than highly ordered fibrils."( Amyloid β Dodecamer Disrupts the Neuronal Membrane More Strongly than the Mature Fibril: Understanding the Role of Oligomers in Neurotoxicity.
Krupa, P; La Penna, G; Li, MS; Linh, HQ; Nguyen, HL, 2022
)
0.72
" Observations of any abnormalities in vital signs, physical examinations, laboratory tests, and electrocardiograms during the study period, along with any spontaneously reported and directly observed adverse events, were documented for safety evaluation."( Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
Ding, Q; Huang, J; Kuang, Y; Pei, Q; Xiao, M; Yang, G; Yang, S; Yang, X; Yao, A, 2023
)
0.91
" Adverse reactions related to GM1 occurred in 20 (28."( Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
Ding, Q; Huang, J; Kuang, Y; Pei, Q; Xiao, M; Yang, G; Yang, S; Yang, X; Yao, A, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters of monosialotetrahexosylganglioside (GM1) have been determined in healthy volunteers at 3 dose levels: 100, 200, 300 mg."( Pharmacokinetics of GM1 ganglioside following parenteral administration.
Baggio, C; Cogo, R; Cornelli, U; Kirschner, G; Panucci, A; Zingali, G, 1990
)
0.28
" Furthermore, neurotoxicity scales were used to assess the efficacy of GM1 as a prophylaxis for chemotherapy-induced peripheral neuropathy and to perform exposure-response analyses in conjunction with pharmacokinetic parameters."( Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
Ding, Q; Huang, J; Kuang, Y; Pei, Q; Xiao, M; Yang, G; Yang, S; Yang, X; Yao, A, 2023
)
0.91
" Covariates such as sex, body weight, and albumin significantly influenced pharmacokinetic parameters, yet the variation in steady-state exposure between subjects and reference subjects was less than 45% within their 90% confidence interval."( Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
Ding, Q; Huang, J; Kuang, Y; Pei, Q; Xiao, M; Yang, G; Yang, S; Yang, X; Yao, A, 2023
)
0.91
"This study provides the first population pharmacokinetic analysis of GM1."( Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
Ding, Q; Huang, J; Kuang, Y; Pei, Q; Xiao, M; Yang, G; Yang, S; Yang, X; Yao, A, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"In order to investigate the antitumor effect of recombinant human interleukin-1 beta (IL-1 beta) alone and in combination with natural human tumor necrosis factor-alpha (nHuTNF-alpha), we used female BDF1 mice bearing Lewis lung carcinoma (3LL)."( Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.
Fuchimoto, S; Ohkura, M; Orita, K, 1990
)
0.28
"To explore the effect and safety of mild hypothermia therapy combined with monosialotetrahexosylganglioside (GM1) on neural function recovery of neonatal asphyxia complicated by hypoxic ischemic encephalopathy (HIE)."( Neural Function Recovery and Safety of Mild Hypothermia Therapy Combined with Monosialotetrahexosylganglioside on Neonatal Asphyxia Complicated by Hypoxic Ischemic Encephalopathy.
Ge, J; Jiao, X; Li, H; Qi, F, 2021
)
0.62
"Mild hypothermia therapy combined with GM1 for the treatment of neonatal asphyxia complicated by HIE can promote the recovery of neural function and reduce the incidence of complications in neonates."( Neural Function Recovery and Safety of Mild Hypothermia Therapy Combined with Monosialotetrahexosylganglioside on Neonatal Asphyxia Complicated by Hypoxic Ischemic Encephalopathy.
Ge, J; Jiao, X; Li, H; Qi, F, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" This increased bioavailability means that GM1lactone can be considered as a potential prodrug of GM1."( Disposition of exogenous tritium-labelled GM1lactone in the rat.
Bellato, P; Facchinetti, E; Milan, F; Toffano, G, 1992
)
0.28
" In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed."( Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K(+)-ATPase activity defects.
Bianchi, R; Figliomeni, B; Fiori, MG; Italiano, G; Marini, P; Paro, M; Prosdocimi, M; Triban, C, 1991
)
0.28
"Due to their poor bioavailability after oral administration, the use of gangliosides in medicine is limited to the parenteral route of administration."( In vitro evaluation of nanoparticle formulations containing gangliosides.
Benedetti, LM; Callegaro, L; Couvreur, P; Polato, L, 1994
)
0.29
" The higher levels of GM1 observed in preterm newborns indicate an increased turnover and/or enhanced bioavailability of the monosialoganglioside GM1 for the developing central nervous system."( Monosialoganglioside GM1 blood levels in maternal and newborn umbilical cord blood at birth.
Kirschner, G; Marchesini, L; Zanardo, V, 1993
)
0.29
"Structural transitions involving shape changes play an important role in cellular physiology and enhance the bioavailability of the natural food like curcumin in surfactant aggregates."( Localization and dynamics of the anticarcinogenic curcumin with GM
Chakrabarti, A; Mandal, M; Mukhopadhyay, C; Patra, M, 2017
)
0.46
" In mice, GLP-1 fused to short-chain glycosphingolipids was rapidly and systemically absorbed after gastric gavage to affect glucose tolerance with serum bioavailability comparable to intraperitoneal injection of GLP-1 alone."( Mucosal absorption of therapeutic peptides by harnessing the endogenous sorting of glycosphingolipids.
Chinnapen, DJ; Garcia-Castillo, MD; Gonzalez, RJ; Kahn, CR; Lau, J; Lencer, WI; Mrsny, RJ; Pacheco, M; Pentelute, BL; Softic, S; Te Welscher, YM; von Andrian, UH, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The limited ability of added GM1 to enhance the toxin's activity appeared in a unique bell-shaped dose-response manner."( Lipolytic action of cholera toxin on fat cells. Re-examination of the concept implicating GM1 ganglioside as the native membrane receptor.
Carter, TP; Kanfer, JN; Katzen, HM, 1976
)
0.26
" Application of solutions of TOPA to cerebellar granule cells resulted in a concentration- and time-dependent neuronal death, with prolonged (24 hr) exposure producing a clear left-handed shift in the dose-response relationship from the one observed with a 60-min exposure (LD50: 4 and 29 microM, respectively)."( Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G, 1992
)
0.28
", saturation-type or Michaelis-Menten kinetics), with MPS uptake decreasing and % of injected dose in blood increasing as dose increased, over the entire dosage range."( Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
Allen, TM; Hansen, C, 1991
)
0.28
"To assess the influence of immaturity on the responsiveness of enterocytes to specific pathogens, a dose-response curve for cholera toxin (CT)-induced fluid secretion was determined in the proximal small intestine of rats at 2 and 4 wk of age."( Age and cortisone alter host responsiveness to cholera toxin in the developing gut.
Chu, SH; Ely, IG; Walker, WA, 1989
)
0.28
" The dose-response curve for inhibition of the generation of NK activity with IL 3 parallelled the growth promoting activity on the strictly IL 3-dependent cell line L/B."( Interleukin 3 is a major negative regulator of the generation of natural killer cells from bone marrow precursors.
Kalland, T, 1986
)
0.27
" A correlation was found between the dose level, duration, and frequency of dosing with rIL-2 required to induce pleural effusions and hepatotoxicity and the dosage regimens required to produce the LAK-like cells in the pleural cavities and livers, respectively, of rIL-2-treated mice."( Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Anderson, TD; Gately, MK; Hayes, TJ, 1988
)
0.27
" This dosage regimen resulted in an approximately 50% reduction of striatal dopamine (DA) level."( Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
Hadjiconstantinou, M; Neff, NH, 1988
)
0.27
" The wv mutation also shows a dosage effect, as granule cell migration is slowed or retarded in the +/wv heterozygotes."( Cellular localization of gangliosides in the developing mouse cerebellum: analysis using the weaver mutant.
Miyazawa, N; Seyfried, TN; Yu, RK, 1983
)
0.27
" The dose-response curve appears in diphase, and the largest magnitude of LTP has been obtained at the GM1 concentration of 50 mg/L in incubation ACSF."( The role of monosialoganglioside GM1 in LTP-induction in rat hippocampal slices.
Li, YX; Mei, ZT, 1994
)
0.29
" A dose-response study showed that treatment with 50, 100, 150, or 200 mM ethanol respectively, for 24 h was positively correlated with membrane lipid lateral mobility and negatively correlated with cell viability."( The membrane disordering effect of ethanol on neural crest cells in vitro and the protective role of GM1 ganglioside.
Chen, SY; Jacobson, K; Sulik, KK; Yang, B,
)
0.13
"The relative affinity of metoclopramide as indicated by K(B) values was calculated in control and in haloperidol-withdrawn rats treated or not with monosialoganglioside-1 (GM1) by using dose-response curves constructed for apomorphine-induced stereotyped behavior."( Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity.
Frussa-Filho, R; Palermo-Neto, J; Vital, MA, 1999
)
0.3
" There was a significant effect in all patients in the primary outcome variable (the percentage of marked recovery) at week 8, the end of the dosing period."( The Sygen multicenter acute spinal cord injury study.
Coleman, WP; Geisler, FH; Grieco, G; Poonian, D, 2001
)
0.31
" We are now conducting a de-escalation dosing study with NP-polySA-KLH to better assess the immunogenicity, toxicities, and optimal dose of this vaccine."( Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Baez, V; Guo, Z; Hood, C; Jennings, HJ; Kris, MG; Krug, LM; Livingston, PO; Miller, V; Ng, KK; Pizzo, B; Ragupathi, G; Tyson, L, 2004
)
0.32
" When the two isoforms are transfected into Kit-225 cells that depend on IL-2 for growth, IL-2Rbeta and gamma, but not alpha subunits are down-regulated, and the -4L, but not the -4S isoform inhibits cell proliferation by 6-fold in an IL-2 dose-response study."( The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor.
Chen, CJ; Shively, JE, 2004
)
0.32
" The latter group suffered approximately 30% mortality, which increased to approximately 75% at dosage of 30 mg/kg KA, compared with 10-14% for the other two genotypes at the latter dosage."( Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant analog of GM1.
Ledeen, RW; Lu, ZH; Meyenhofer, MF; Wang, J; Wang, Y; Wu, G; Xie, X, 2005
)
0.33
" This effect was shown by the lower dosage of cocaine necessary to induce conditioning compared with rats receiving cocaine alone, as well as by the fewer number of sessions necessary to induce place preference."( GM1 ganglioside enhances the rewarding properties of cocaine in rats.
Cuadra, GR; de Burgos, NG; Hansen, C; Orsingher, OA; Valdomero, A, 2010
)
0.36
" (2) There was characteristic dose-response relationship between GM1 and TTC staining of rat hippocampal slices."( [Study on protective effect of monosialoganglioside (GM1) on injury induced by oxygen glucose deprivation/reperfusion in rat hippocampal slices].
Ge, QF; Li, W; Liu, JR; Liu, RY; Song, SJ; Wang, ML; Wei, EQ, 2003
)
0.32
" We previously described that exogenous GM1 ganglioside pretreatment enhances the rewarding properties of cocaine, evidenced by a lower number of sessions and/or dosage necessary to induce conditioned place preference (CPP)."( Exogenous GM1 ganglioside increases accumbal BDNF levels in rats.
Cuadra, GR; Orsingher, OA; Perondi, MC; Valdomero, A, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sialotetraosylceramideA ganglioside in which the oligosaccharide portion is composed of an tetrasaccharide, to which one or more sialic acid residues are attached.
alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosineA sialotetraosylceramide having beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc as the sialotetraosyl component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (3,983)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901004 (25.21)18.7374
1990's1338 (33.59)18.2507
2000's891 (22.37)29.6817
2010's584 (14.66)24.3611
2020's166 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials73 (1.77%)5.53%
Reviews223 (5.41%)6.00%
Case Studies227 (5.51%)4.05%
Observational1 (0.02%)0.25%
Other3,596 (87.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]